Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer Sep 22, 2021
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Sep 15, 2021
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia Aug 18, 2021
Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131 Aug 16, 2021
Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update Aug 9, 2021
Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs) Jul 12, 2021
Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors Jun 24, 2021
Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Jun 4, 2021